{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:25:25Z","timestamp":1771053925063,"version":"3.50.1"},"reference-count":18,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"DOI":"10.1182\/bloodadvances.2025016176","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T16:22:45Z","timestamp":1752682965000},"page":"4673-4675","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2305-9638","authenticated-orcid":false,"given":"Fausto Alfredo","family":"Rios-Olais","sequence":"first","affiliation":[{"name":"1Hematology and Oncology Department, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-4128","authenticated-orcid":false,"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"4","key":"2025092310215644200_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"2025092310215644200_bib2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"2025092310215644200_bib3","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025092310215644200_bib4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2025092310215644200_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2025092310215644200_bib6","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"2025092310215644200_bib7","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2025092310215644200_bib8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/bloodadvances.2023011184","article-title":"Estimation of eligibility for and response to CAR-T therapy in the United States","volume":"8","author":"Haslam","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2025092310215644200_bib9","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025092310215644200_bib10","unstructured":"American Cancer Society\n          . Cancer Facts & Figures 2024. Accessed 1 August 2025. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures.html."},{"issue":"9","key":"2025092310215644200_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2025092310215644200_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"2025092310215644200_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025092310215644200_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-023-00883-x","article-title":"Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","volume":"13","author":"McCurdy","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025092310215644200_bib15","doi-asserted-by":"crossref","first-page":"e432204","DOI":"10.1200\/EDBK_432204","article-title":"Charting the course: sequencing immunotherapy for multiple myeloma","volume":"44","author":"Mohan","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"2025092310215644200_bib16","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3324\/haematol.2024.285255","article-title":"Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma","volume":"109","author":"Melody","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"2025092310215644200_bib17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2024013640","article-title":"Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas","volume":"9","author":"Chong","year":"2025","journal-title":"Blood Adv"},{"key":"2025092310215644200_bib18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014903","article-title":"Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","author":"Shumilov","year":"11  2024","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4673\/2412318\/blooda_adv-2025-016176-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4673\/2412318\/blooda_adv-2025-016176-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:35:00Z","timestamp":1758638100000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/18\/4673\/546201\/Estimation-of-benefit-to-bispecific-antibodies-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":18,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016176","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,23]]},"published":{"date-parts":[[2025,9,12]]}}}